{'text': 'Harvard Pilgrim cements risk-based contract for pricey cholesterol drug Repatha', 'publisher': {'href': 'https://www.modernhealthcare.com', 'title': 'Modern Healthcare'}, 'created_at': 'Sun, 08 Nov 2015 08:00:00 GMT', 'description': 'Harvard Pilgrim cements risk-based contract for pricey cholesterol drug Repatha  Modern Healthcare', 'url': 'https://news.google.com/rss/articles/CBMi3AFBVV95cUxQMmxlT09rRk9UcEVHVVRHSXlzbk1pbm1xYjNjUG1DM1NLMmRBeGRhd29fSWZibVpiQlIyMkl2Q1VudUxpXy1tMjViSWlERTRjQ1hKS1RCbmYtR1FYYVJUUkV1bXpjNmFTNXA3YU5KYnJYVXVFS3ZXclRCZ05LTTQwOW1wWUNUTFdzeFBNNTIyOWdJOW9YQ0pRM0hzaHZ0bXBoS2hhenVzMDZVRmRsNno1aHl1MndELXBUemxVMzRpZ3cwZ1ZWSXNQVm9mdHQtUlFVTDRzQXljel9sc2ZC?oc=5&hl=en-US&gl=US&ceid=US:en'}
